CCL21/CCR7 axis activating chemotaxis accompanied with epithelial–mesenchymal transition in human breast carcinoma

Medical Oncology

Volumn 31, Issue 9, 2014, Pages 1-10

  Li, Fei ^a   Zou, Zhigeng ^b   Suo, Ning ^a   Zhang, Zongpu ^a   Wan, Fangzhu ^a   Zhong, Guangxin ^a   Qu, Yan ^a   Ntaka, Kwanele Siphelele ^a   Tian, Hua ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Breast cancer cells; CCL21; CCR7; Chemotaxis; Epithelial mesenchymal transition; Lymph node metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR7; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; VIMENTIN; CCL21 PROTEIN, HUMAN; CCR7 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER CELL; CANCER STAGING; CELL INVASION; CELL MIGRATION; CHEMORADIOTHERAPY; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MCF 7 CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; BREAST; BREAST TUMOR; CHEMISTRY; GENE SILENCING; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL21; CHEMOTAXIS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; RECEPTORS, CCR7; TUMOR MARKERS, BIOLOGICAL;

EID: 84906008237     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0180-8     Document Type: Article

References (35)

1. Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23(3):505–23.
2. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742–57.
3. Grabau D, Dihge L, Fernö M, Ingvar C, Rydén L. Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade’s experience from a single institution. Eur J Surg Oncol. 2013;39(6):601–7.
4. Mukaida N, Baba T. Chemokines in tumor development and progression. Exp Cell Res. 2012;318(2):95–102.
5. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes. Proc Natl Acad Sci USA. 1998;95(1):258–63.
6. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, et al. The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001;193:1105–12.
7. Carlsen HS, Haraldsen G, Brandtzaeg P, Baekkevold ES. Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood. 2005;106(2):444–6.
8. Forster R, Valos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8:362–71.
9. Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-Bordas J, Martin D, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 2004;104:619–25.
10. Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naïve T cells. Nat Immunol. 2007;8(11):1255–65.
11. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026–9.
12. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.
13. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–100.
14. Taki M, Higashikawa K, Yoneda S, Ono S, Shigeishi H, Nagayama M, et al. Up-regulation of stromal cell-derived factor-1alpha and its receptor CXCR4 expression accompanied with epithelial–mesenchymal transition in human oral squamous cell carcinoma. Oncol Rep. 2008;19(4):993–8.
15. Bertran E, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM, et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial–mesenchymal transition in response to the transforming growth factor-beta. Cell Signal. 2009;21(11):1595–606.
16. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial–mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett. 2012;322(2):169–76.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−ΔΔ C (T)) Method. Methods. 2001;25(4):402–8.
18. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.
19. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005;11(16):5686–93.
20. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010;29:16. doi:10.1186/1756-9966-29-16.
21. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003;105:186–9.
22. Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res. 2003;9:3406–12.
23. Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002;62(10):2937–41.
24. Gunther K, Leier J, Henning G, Dimmler A, Weissbach R, Hohenberger W, et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int J Cancer. 2005;116:726–33.
25. Sancho M, Vieira JM, Casalou C, Mesquita M, Pereira T, Cavaco BM, et al. Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. J Endocrinol. 2006;191(1):229–38.
26. Oliveira-Neto HH, de Souza PP, da Silva MR, Mendonça EF, Silva TA, Batista AC. The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis. Tumour Biol. 2013;34:65–70.
27. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, Slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12(6):488–96.
28. Nagi C, Guttman M, Jaffer S, Qiao R, Keren R, Triana A, et al. N-Cadherin expression in breast cancer: correlation with an aggressive histologic variant-invasive micropapillary carcinoma. Breast Cancer Res Treat. 2005;94(3):225–35.
29. Mumtaz M, Wågsäter D, Löfgren S, Hugander A, Zar N, Dimberg J. Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas. Oncol Rep. 2009;21(1):153–8.
30. Sperveslage J, Frank S, Heneweer C, Egberts J, Schniewind B, Buchholz M, et al. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Int J Cancer. 2012;131(4):E371–81.
31. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell. 2007;11(6):526–38.
32. Guo N, Liu F, Yang L, Huang J, Ding X, Sun C. Chemokine receptor 7 enhances cell chemotaxis and migration of metastatic squamous cell carcinoma of head and neck through activation of matrix metalloproteinase-9. Oncol Rep. 2014;32(2):794–800.
33. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121(Pt 6):727–35.
34. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511.
35. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436–48.